Community-acquired pneumonia

New England Journal of Medicine

Volumn 371, Issue 17, 2014, Pages 1619-1628

  Musher, Daniel M ^a,b   Thorner, Anna R ^c  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; IMMUNOMODULATING AGENT;

BLOOD CULTURE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HEALTH CARE SYSTEM; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; INFECTION RISK; INFECTION SENSITIVITY; MEDICAL RESEARCH; MICROSCOPY; MORAXELLA CATARRHALIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; QUANTITATIVE DIAGNOSIS; REVIEW; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; TREATMENT RESPONSE; COMMUNITY ACQUIRED INFECTION; DRUG ADMINISTRATION; MORTALITY; PNEUMONIA;

ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; HOSPITALIZATION; HUMANS; PNEUMONIA; PRACTICE GUIDELINES AS TOPIC;

EID: 84901468713     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1312885     Document Type: Review

References (108)

1. Heffron R. Pneumonia, with special reference to pneumococcus lobar pneumonia. Cambridge, MA: Harvard University Press, 1939.
2. Gray BM, Musher DM. The history of pneumococcal disease. In: Siber G, Klugman KP, Makela P, eds. Pneumococcal vaccines: the impact of conjugate vaccine. Washington, DC: ASM Press, 2008:3-17.
3. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for communityacquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine (Baltimore) 1990;69:307-16.
4. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with communityacquired pneumonia. Clin Infect Dis 2010; 51:1395-405.
5. Erratum, Clin Infect Dis 2011;52:967.
6. Musher DM, Roig IL, Cazares G, Stager CE, Logan N, Safar H. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect 2013;67:11-8.
7. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 2008;133:610-7.
8. Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ?50 years with community-acquired pneumonia. J Infect Dis 2013;208:1813-20.
9. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013;1:CD000422.
10. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CGUS. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013;369:155-63.
11. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. N Engl J Med 2000;342: 681-9.
12. Current cigarette smoking among adults - United States, 2011. MMWR Morb Mortal Wkly Rep 2012;61:889-94.
13. Huijts SM, Pride MW, Vos JM, et al. Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia. Eur Respir J 2013;42:1283-90.
14. Rozenbaum MH, Pechlivanoglou P, van der Werf TS, Lo-Ten-Foe JR, Postma MJ, Hak E. The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis 2013;32:305-16.
15. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:Suppl 2:S27-S72.
16. Falguera M, Carratalà J, Ruiz-Gonzalez A, et al. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Respirology 2009; 14:105-11.
17. Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010;50:202-9.
18. Beovic B, Bonac B, Kese D, et al. Aetiology and clinical presentation of mild community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 2003;22:584-91.
19. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza - Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007;56:325-9.
20. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep 2009;58:1071-4.
21. Sheng ZM, Chertow DS, Ambroggio X, et al. Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. Proc Natl Acad Sci U S A 2011;108:16416-21.
22. Oosterheert JJ, van Loon AM, Schuurman R, et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis 2005;41:1438-44.
23. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008;134:1141-8.
24. Pavia AT. What is the role of respiratory viruses in community-acquired pneumonia?: What is the best therapy for influenza and other viral causes of community- acquired pneumonia? Infect Dis Clin North Am 2013;27:157-75.
25. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13:752-61.
26. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277-85.
27. Erratum, N Engl J Med 2013; 369:1869.
28. Cillóniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011;66:340-6.
29. Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005; 99:60-5.
30. Esposito AL. Community-acquired bacteremic pneumococcal pneumonia: effect of age on manifestations and outcome. Arch Intern Med 1984;144:945-8.
31. Polverino E, Torres A, Menendez R, et al. Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study. Thorax 2013;68:1007-14.
32. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997;157: 1453-9.
33. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93.
34. Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004;39:165-9.
35. Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013;8(4):e60273.
36. Musher DM, McKenzie SO. Infections due to Staphylococcus aureus. Medicine (Baltimore) 1977;56:383-409.
37. Gutiérrez F, Masiá M, Rodríguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of communityacquired pneumonia in Spain. Clin Infect Dis 2003;36:286-92.
38. Boulware DR, Daley CL, Merrifield C, Hopewell PC, Janoff EN. Rapid diagnosis of pneumococcal pneumonia among HIVinfected adults with urine antigen detection. J Infect 2007;55:300-9.
39. Smith MD, Sheppard CL, Hogan A, et al. Diagnosis of Streptococcus pneumoniae infections in adults with bacteremia and community-acquired pneumonia: clinical comparison of pneumococcal PCR and urinary antigen detection. J Clin Microbiol 2009;47:1046-9.
40. Shimada T, Noguchi Y, Jackson JL, et al. Systematic review and metaanalysis: urinary antigen tests for Legionellosis. Chest 2009;136:1576-85.
41. Blazquez RM, Espinosa FJ, Martinez-Toldos CM, Alemany L, Garcia-Orenes MC, Segovia M. Sensitivity of urinary antigen test in relation to clinical severity in a large outbreak of Legionella pneumonia in Spain. Eur J Clin Microbiol Infect Dis 2005;24:488-91.
42. Poritz MA, Blaschke AJ, Byington CL, et al. FilmArray, an automated nested multiplex PCR system for multi-pathogen detection: development and application to respiratory tract infection. PLoS One 2011;6(10):e26047.
43. Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med 2012;156:500-11.
44. Falsey AR, Becker KL, Swinburne AJ, et al. Bacterial complications of respiratory tract viral illness: a comprehensive evaluation. J Infect Dis 2013;208:432-41.
45. Sangil A, Calbo E, Robles A, et al. Aetiology of community-acquired pneumonia among adults in an H1N1 pandemic year: the role of respiratory viruses. Eur J Clin Microbiol Infect Dis 2012;31:2765-72.
46. Str.lin K. Usefulness of aetiological tests for guiding antibiotic therapy in community-acquired pneumonia. Int J Antimicrob Agents 2008;31:3-11.
47. Albrich WC, Madhi SA, Adrian PV, et al. Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumonia. Clin Infect Dis 2012;54:601-9.
48. Chalmers JD, Mandal P, Singanayagam A, et al. Severity assessment tools to guide ICU admission in communityacquired pneumonia: systematic review and meta-analysis. Intensive Care Med 2011;37:1409-20.
49. Wiemken T, Kelley R, Ramirez J. Clinical scoring tools: which is best to predict clinical response and long-term outcomes? Infect Dis Clin North Am 2013;27: 33-48.
50. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
51. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82.
52. Chalmers JD, Taylor JK, Mandal P, et al. Validation of the Infectious Diseases Society of America/American Thoracic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis 2011;53:503-11.
53. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008;47:375-84.
54. Abers MS, Musher DM. Clinical prediction rules in community-acquired pneumonia: lies, damn lies and statistics. QJM 2014;107:595-6.
55. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64:Suppl 3:iii1- iii55.
56. Spindler C, Strulin K, Eriksson L, et al. Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults - Swedish Society of Infectious Diseases 2012. Scand J Infect Dis 2012;44:885-902.
57. Johnstone J, Mandell L. Guidelines and quality measures: do they improve outcomes of patients with communityacquired pneumonia? Infect Dis Clin North Am 2013;27:71-86.
58. Frei CR, Attridge RT, Mortensen EM, et al. Guideline-concordant antibiotic use and survival among patients with community- acquired pneumonia admitted to the intensive care unit. Clin Ther 2010; 32:293-9.
59. Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007; 131:1865-9.
60. Welker JA, Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med 2008;168: 351-6.
61. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005;41:139-48.
62. Kim SH, Song JH, Chung DR, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother 2012;56:1418-26.
63. Johnstone J, Eurich DT, Majumdar SR, Jin Y, Marrie TJ. Long-term morbidity and mortality after hospitalization with community- acquired pneumonia: a population- based cohort study. Medicine (Baltimore) 2008;87:329-34.
64. Metersky ML, Waterer G, Nsa W, Bratzler DW. Predictors of in-hospital vs postdischarge mortality in pneumonia. Chest 2012;142:476-81.
65. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007;45:1568-75.
66. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012;55: 1198-204.
67. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(1):1-24.
68. Fernández-Sabé N, Rosón B, Carratalà J, Dorca J, Manresa F, Gudiol F. Clinical diagnosis of Legionella pneumonia revisited: evaluation of the Community-Based Pneumonia Incidence Study Group scoring system. Clin Infect Dis 2003;37:483-9.
69. Fiumefreddo R, Zaborsky R, Haeuptle J, et al. Clinical predictors for Legionella in patients presenting with communityacquired pneumonia to the emergency department. BMC Pulm Med 2009;9:4.
70. Helms CM, Viner JP, Sturm RH, Renner ED, Johnson W. Comparative features of pneumococcal, mycoplasmal, and Legionnaires' disease pneumonias. Ann Intern Med 1979;90:543-7.
71. Sopena N, Pedro-Botet ML, Sabrià M, García-Parés D, Reynaga E, García-Nuez M. Comparative study of community acquired pneumonia caused by Streptococcus pneumoniae, Legionella pneumophila or Chlamydia pneumoniae. Scand J Infect Dis 2004;36:330-4.
72. Woodhead MA, Macfarlane JT. Comparative clinical and laboratory features of legionella with pneumococcal and mycoplasma pneumonias. Br J Dis Chest 1987;81:133-9.
73. Foy HM, Grayston JT, Kenny GE, Alexander ER, McMahan R. Epidemiology of Mycoplasma pneumoniae infection in families. JAMA 1966;197:859-66.
74. Afzal Z, Minard CG, Stager CE, Yu VL, Musher DM. Clinical diagnosis, viral PCR, and antibiotic utilization in community- acquired pneumonia. Am J Ther 2013 December 17 (Epub ahead of print).
75. Schuetz P, Müller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012;9:CD007498.
76. Townsend EH Jr, Decancq HG Jr. Pneumococcic segmental (lobar) pneumonia: its treatment with a single injection of procaine penicillin G. Clin Pediatr (Phila) 1965;4:117-22.
77. Sutton DR, Wicks AC, Davidson L. One-day treatment for lobar pneumonia. Thorax 1970;25:241-4.
78. Wood WB Jr. Pneumonia. In: Cecil RL, Loeb RF, eds. A textbook of medicine. 10th ed. Philadelphia: W.B. Saunders, 1959:113-30.
79. Jenkinson SG, George RB, Light RW, Girard WM. Cefazolin vs penicillin: treatment of uncomplicated pneumococcal pneumonia. JAMA 1979;241:2815-7.
80. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007;120: 783-90.
81. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004;20:555-63.
82. Erratum, Curr Med Res Opin 2004;20:967.
83. el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate- severe community acquired pneumonia: randomised, double blind study. BMJ 2006;332:1355.
84. Scalera NM, File TM Jr. Determining the duration of therapy for patients with community-acquired pneumonia. Curr Infect Dis Rep 2013;15:191-5.
85. Mandell LA, File TM Jr. Short-course treatment of community-acquired pneumonia. Clin Infect Dis 2003;37:761-3.
86. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18- e55.
87. Erratum, Clin Infect Dis 2011;53:319.
88. Desaki M, Takizawa H, Ohtoshi T, et al. Erythromycin suppresses nuclear factorkappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000;267:124-8.
89. Shorr AF, Zilberberg MD, Kan J, Hoffman J, Micek ST, Kollef MH. Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study. BMJ Open 2013;3(6):pii:e002898.
90. Corrales-Medina VF, Musher DM. Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review. J Infect 2011;63:187-99.
91. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9.
92. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90.
93. Svanstrom H, Pasternak B, Hviid A. Cardiovascular risks with azithromycin. N Engl J Med 2013;369:580-1.
94. Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014;311:2199-208.
95. Papazian L, Roch A, Charles PE, et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA 2013;310:1692-700.
96. Madjid M, Miller CC, Zarubaev VV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J 2007;28:1205-10.
97. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis 2009;9:601-10.
98. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007;45:158-65.
99. Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008;47:182-7.
100. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010;10:83-92.
101. Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012;125:773-81.
102. Bazaz R, Marriott HM, Francis SE, Dockrell DH. Mechanistic links between acute respiratory tract infections and acute coronary syndromes. J Infect 2013; 66:1-17.
103. Viasus D, Garcia-Vidal C, Manresa F, Dorca J, Gudiol F, Carratalà J. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community- acquired pneumonia. J Infect 2013; 66:27-33.
104. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013;309:355-63.
105. Bruns AH, Oosterheert JJ, El Moussaoui R, Opmeer BC, Hoepelman AI, Prins JM. Pneumonia recovery: discrepancies in perspectives of the radiologist, physician and patient. J Gen Intern Med 2010;25: 203-6.
106. Metlay JP, Fine MJ, Schulz R, et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med 1997;12:423-30.
107. Sandvall B, Rueda AM, Musher DM. Long-term survival following pneumococcal pneumonia. Clin Infect Dis 2013; 56:1145-6.
108. Bruns AH, Oosterheert JJ, Cucciolillo MC, et al. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. Clin Microbiol Infect 2011;17:763-8.